EMA Authorised: Halaven (Eribulin) — Eisai GmbH

View source ↗

Summary

The EMA authorised Halaven (eribulin) for breast neoplasms and liposarcoma under Eisai GmbH, with a decision date of 26 July 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Liposarcoma

Drugs mentioned

• Halaven (eribulin)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Liposarcoma. MAH: Eisai GmbH. Decision date: 26/07/2024